Prognostic Factors of Melanoma Patients with Satellite or In-Transit Metastasis at the Time of Stage III Diagnosis

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Weide, Benjamin ^a   Faller, Christine ^a   Büttner, Petra ^b   Pflugfelder, Annette ^a   Leiter, Ulrike ^a   Eigentler, Thomas Kurt ^a   Bauer, Jürgen ^a   Forschner, Andrea ^a   Meier, Friedegund ^a   Garbe, Claus ^a,b  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b JAMES COOK UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE SPECIFIC SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MELANOMA; SKIN METASTASIS; SKINFOLD THICKNESS; ULCER; KAPLAN MEIER METHOD; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SECONDARY; SKIN TUMOR;

AGED; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SKIN NEOPLASMS;

EID: 84876943170     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0063137     Document Type: Article

References (20)

1. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, et al. (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27: 6199-6206.
2. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Ding S, et al. (2010) Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol 28: 2452-2459.
3. Singletary SE, Tucker SL, Boddie AW Jr, (1988) Multivariate analysis of prognostic factors in regional cutaneous metastases of extremity melanoma. Cancer 61: 1437-1440.
4. Sutherland CM, Mather FJ, Krementz ET, (1987) Factors influencing the survival of patients with regional melanoma of the extremity treated by perfusion. Surg Gynecol Obstet 164: 111-118.
5. Karakousis CP, Temple DF, Moore R, Ambrus JL, (1983) Prognostic parameters in recurrent malignant melanoma. Cancer 52: 575-579.
6. Soong SJ, Harrison RA, McCarthy WH, Urist MM, Balch CM, (1998) Factors affecting survival following local, regional, or distant recurrence from localized melanoma. J Surg Oncol 67: 228-233.
7. Messeguer F, Agusti-Mejias A, Traves V, Requena C, Alegre V,et al. (2012) Mitotic rate and subcutaneous involvement are prognostic factors for survival after recurrence in patients with only locoregional skin metastasis as the first site of recurrence from cutaneous melanoma. J Eur Acad Dermatol Venereol (published online first).
8. Eggermont AM, Suciu S, Santinami M, Testori A, Kruit WH, et al. (2008) Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet 372: 117-126.
9. Garbe C, Radny P, Linse R, Dummer R, Gutzmer R, et al. (2008) Adjuvant low-dose interferon {alpha}2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis. Ann Oncol 19: 1195-1201.
10. Kirkwood JM, Ibrahim JG, Sosman JA, Sondak VK, Agarwala SS, et al. (2001) High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 19: 2370-2380.
11. Lasithiotakis KG, Leiter U, Eigentler T, Breuninger H, Metzler G, et al. (2007) Improvement of overall survival of patients with cutaneous melanoma in Germany, 1976-2001: which factors contributed? Cancer 109: 1174-1182.
12. Francken AB, Accortt NA, Shaw HM, Wiener M, Soong SJ, et al. (2008) Prognosis and determinants of outcome following locoregional or distant recurrence in patients with cutaneous melanoma. Ann Surg Oncol 15: 1476-1484.
13. Roses DF, Karp NS, Oratz R, Dubin N, Harris MN, et al. (1991) Survival with regional and distant metastases from cutaneous malignant melanoma. Surg Gynecol Obstet 172: 262-268.
14. Essner R, Lee JH, Wanek LA, Itakura H, Morton DL, (2004) Contemporary surgical treatment of advanced-stage melanoma. Arch Surg 139: 961-966.
15. Kretschmer L, Preusser KP, Marsch WC, Neumann C, (2000) Prognostic factors of overall survival in patients with delayed lymph node dissection for cutaneous malignant melanoma. Melanoma Res 10: 483-489.
16. Weide B, Elsasser M, Buttner P, Pflugfelder A, Leiter U, et al. (2012) Serum markers lactate dehydrogenase and S100B predict independently disease outcome in melanoma patients with distant metastasis. Br J Cancer 107: 422-428.
17. Saleh FH, Crotty KA, Hersey P, Menzies SW, (2001) Primary melanoma tumour regression associated with an immune response to the tumour-associated antigen melan-A/MART-1. Int J Cancer 94: 551-557.
18. Lee CC, Faries MB, Wanek LA, Morton DL, (2008) Improved survival after lymphadenectomy for nodal metastasis from an unknown primary melanoma. J Clin Oncol 26: 535-541.
19. Prens SP, van der Ploeg AP, van Akkooi AC, van Montfort CA, van Geel AN,et al. (2011) Outcome After Therapeutic Lymph Node Dissection in Patients with Unknown Primary Melanoma Site. Ann Surg Oncol.
20. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, et al. (2001) Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19: 3635-3648.